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Because cord blood (CB) lacks memory T and B cells and recent decreases in herd immunity to vaccine-
preventable diseases in many developed countries have been documented, vaccine responses in CB trans-
plantation (CBT) survivors are of great interest. We analyzed vaccine responses in double-unit CBT recipients
transplanted for hematologic malignancies. In 103 vaccine-eligible patients, graft-versus-host disease (GVHD)
most commonly precluded vaccination. Sixty-ﬁve patients (63%; engrafting units median HLA-allele match
5/8; range, 2 to 7/8) received protein conjugated vaccines, and 63 patients (median age, 34 years; range, .9 to
64) were evaluated for responses. Median vaccination time was 17 months (range, 7 to 45) post-CBT. GVHD
(n ¼ 42) and prior rituximab (n ¼ 13) delayed vaccination. Responses to Prevnar 7 and/or 13 vaccines (se-
rotypes 14, 19F, 23F) were seen in children and adults (60% versus 49%, P ¼ .555). Responses to tetanus,
diphtheria, pertussis, Haemophilus inﬂuenzae, and polio were observed in children (86% to 100%) and adults
(53% to 89%) even if patients had prior GVHD or rituximab. CD4þCD45RAþ and CD19þ cell recovery signiﬁ-
cantly inﬂuenced tetanus and polio responses. In a smaller cohort responses were seen to measles (65%),
mumps (50%), and rubella (100%) vaccines. No vaccine side effects were identiﬁed, and all vaccinated patients
survived (median follow-up, 57 months). Although GVHD and rituximab can delay vaccination, CBT recipients
(including adults and those with prior GVHD) have similar vaccine response rates to adult donor allograft
recipients supporting vaccination in CBT recipients.
 2015 American Society for Blood and Marrow Transplantation.INTRODUCTION recipients are of great clinical relevance. Moreover, vaccine
Disease-free survival after cord blood transplantation
(CBT) is comparable with that of adult donor allografts in
many series [1-8]. With increasing survivorship and the loss
of pretransplant immunity, vaccine responses in CBTedgments on page 2164.
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ty for Blood and Marrow Transplantation.responses may differ from those observed after adult donor
unmodiﬁed hematopoietic stem cell transplantation because
of the lack of transfer of memory T and B cells capable of
peripheral expansion. As in all allograft recipients, responses
could be altered by the development of graft-versus-host
disease (GVHD). Vaccine responses are also of scientiﬁc in-
terest in CBT survivors because they are an excellent test of
immune competence. Although several groups have evalu-
ated the kinetics of immune recovery after single- and
double-unit CBT [9-16], no data exist examining vaccine re-
sponses in CBT recipients. Many centers vaccinate at ﬁxed
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precluding evaluation of vaccine efﬁcacy. Documentation of
vaccine efﬁcacy is especially important in older patients,
those with clinically signiﬁcant GVHD, and patients who
have received peri- or post-CBT rituximab who are at
particular risk of negligible or inadequate responses.
Memorial Sloan Kettering Cancer Center practice has
increasingly been to initiate vaccines once patients have
achieved immunological milestones with measurement of
pre- and post-titers to evaluate responses. This is appropriate
in CBT recipients given the lack of data concerning vaccine
responses. We examined the incidence and time to vacci-
nation, the incidence of severe vaccine side effects, responses
to protein conjugated vaccines, and survival after vaccination
in double-unit CBT recipients transplanted for hematological
malignancies at our center. In a smaller cohort of patients, we
also evaluated responses to live vaccines. Our hypothesis was
that although GVHD and/or the administration of rituximab
could prevent or delay vaccination, CBT recipients could
otherwise respond to nonlive vaccines similar to adult donor
allograft recipients.METHODS
Patients
All consecutive CBT recipients treated for hematological malignancies at
Memorial Sloan Kettering Cancer Center from October 2005 to February
2012 were reviewed for study inclusion. Patients eligible for this retro-
spective analysis included recipients of a ﬁrst allograft for the treatment of
high-risk or advanced hematological malignancies who were engrafted and
disease-free at 6 months post-CBT (the earliest time point that vaccines
were considered) and had pre- and post-vaccine titers. All patients received
double-unit grafts that were 4-6/6 HLA-A, -B antigen, -DRB1 allele matched
to the recipient as previously published [19]. High-resolution typing for class
I HLA alleles was also performed. Patients predominantly received ﬂudar-
abine and total body irradiationebased conditioning, although a small
cohort received chemotherapy-only preparative regimens [5,20,21].
Immunosuppression therapy was given as previously described with a cal-
cineurin inhibitor and mycophenolate mofetil without antithymocyte
globulin [5,14]. Permission to use clinical and laboratory information was
obtained from the Institutional Review/Privacy Board.Vaccines and Deﬁnitions of Response
The primary series included protein conjugated vaccines as follows:
pneumococcal vaccine (Prevnar 7, which was replaced by Prevnar 13 in
2010); tetanus, diphtheria, and pertussis (Tdap; usually given as Boostrix 8
mg/dose);Haemophilus inﬂuenzae type b (HiB); and inactivated polio vaccine.
Patients were also offered hepatitis B vaccine given as Twinrix (hepatitis A
and B combination), hepatitis B recombinant vaccine, or Pediarix (which
also contains tetanus, diphtheria, and polio). Most clinicians vaccinated
patients after 6 months (usually after 1 year in adults) and achievement of
basic immune milestones (CD4þ count > 200 cells/mL and IgG level > 500
mg/dL independent of intravenous immunoglobulin replacement) who
were on no or minimal immune suppression. Some clinicians also consid-
ered phytohemagglutinin responses [14], and, more recently, a CD19þ count
> 50 cells/mL has also been included in the guidelines for vaccine initiation.
Prevaccine titers were measured by ELISA and were drawn before vac-
cine initiation. Three doses of Prevnar 7 or 13, Tdap, and HiB ( hepatitis B
vaccines) were recommended at time 0 and at þ1 month and þ2 months,
but only 2 doses of polio vaccine (time 0 and þ1 month) with titers were
given 1 to 3 months later. A response was deﬁned as seroconversion in a
seronegative individual, a 3-fold geometric mean fold rise of the IgG geo-
metric mean concentration, or 2-fold for pertussis. The Architect i2000R
instrument (Abbott, Abbott Park, IL, USA) was used for hepatitis B titers with
the manufacturer cut-off <8.0 mIU/mL for negative and 12.00 mIU/mL for
positive. For the purposes of analysis, patients were categorized as having a
pneumococcal vaccine response if they had a >3-fold rise in titers against
the clinically signiﬁcant serotypes 14, 19F, and 23F found in both Prevnar 7
and Prevnar 13 because these serotypes can cause resistant invasive infec-
tion after hematopoietic cell transplantation [22,23]. Polio response was
deﬁned as response to all 3 serotypes. Boosters were recommended in pa-
tients without a response to the primary series, although subsequent
assessment of vaccine efﬁcacy was inﬂuenced by frequency of patient
follow-up.Patients off immune suppression, without active GVHD, and with
documented responses to at least 2 primary series vaccines who were
seronegative were offered live vaccines (measles, mumps, and rubella
[MMR]). Patients received 1 to 2 doses of the MMR vaccine. Response was
deﬁned as seroconversion in a seronegative individual or a 3-fold geometric
mean fold rise of the IgG geometric mean concentration.
Statistical Analysis
Children were deﬁned as aged <16 years of age. Acute and chronic
GVHD were graded according to Center for International Blood and Marrow
Transplant Research [24] and National Institutes of Health [25] criteria,
respectively. Clinically signiﬁcant GVHD was deﬁned as grades II to IV acute
GVHD and/or moderate to severe chronic GVHD. Low-dose immunosup-
pression therapy was deﬁned as calcineurin inhibitor level less than half the
lower limit of therapeutic range, <.2 mg/kg per day of prednisone, and/or
other immunosuppressive agent prescribed at less than half the therapeutic
dose. Comparisons of time to vaccination used the Mann-Whitney U test,
whereas the assessment of factors associated with vaccine responses used
the Fisher’s exact test (2-sided). A P < .05 was considered statistically
signiﬁcant.
RESULTS
Eligibility for Vaccination
Of 143 patients transplanted during the study period, 103
(72%) were disease-free at 6 months post-CBT and potentially
eligible for vaccines. Of the 103 patients, 65 (63%) were vacci-
nated with the primary series protein conjugated vaccines.
Sixty-three of these patients were assessable for vaccine re-
sponses because they had long-term follow-up with both pre-
and post-vaccine titers, whereas 2 patients left the New York
area and did not have post-vaccine titers and were excluded.
The remaining 38 patients (37%) were not vaccinated at the
time of analysis primarily because of GVHD administration of
rituximab (n ¼ 28, including 12 rituximab). Other reasons for
lack of vaccination included relapse (n ¼ 6), corticosteroids for
pulmonary disease (n ¼ 2), or loss to follow-up (n ¼ 2).
Characteristics of Patients Evaluated for Vaccine
Responses
The patient and graft demographics of the 63 assessable
vaccinated patients are listed in Table 1. Patients (median age,
34 years) predominantly had acute leukemia (67%) and
received high-dose (51%) or intermediate-intensity but func-
tionally myeloablative (32%) conditioning. Engrafting units
had a high degree of donorerecipient HLAmismatch. Thirteen
patients (21%) received rituximab as part of the preparative
regimen (n ¼ 6), as treatment for CD20þ relapse (n ¼ 1), as
part of both the conditioning and treatment of relapse (n¼ 1),
and as treatment for Epstein-Barr viremia (n ¼ 3), of RBC
aplasia (n ¼ 1), or of autoimmune hemolysis (n ¼ 1). The last
dose of rituximabwas given amedian of 15months (range, 3.0
to 35) before the commencement of vaccination.
Most vaccinated patients (n ¼ 38, 60%) had grades II to IV
acute GVHD before day 180 post-CBT. Ten patients had pre-
viously had chronic GVHD (6 with prior acute GVHD and 4
with de novo disease). Thus, 42 of 63 patients (67%) had
acute and/or chronic GVHD before vaccination. Eighteen of
63 patients (29%) were vaccinated while on low-dose im-
mune suppression, whereas immunosuppression had been
stopped in the remainder. CD4þ and CD19þ cell counts and
IgG levels were adequate in most patients, although there
was a wide range of immune recovery immediately before
vaccine initiation.
Time to Vaccination Initiation
The 63 assessable patients were vaccinated at a median of
17 months post-CBT (range, 7 to 45). Within this group
vaccination was delayed in the rituximab recipients (19
Figure 1. Prevnar response for 3 clinically signiﬁcant pneumococcal serotypes
(14, 19F, and 23F) in 58 double-unit CBT recipients. Responses are split by
children (n ¼ 15) and adults (n ¼ 43).
Figure 2. Primary series responses for Tdap, HiB, and polio in double-unit
CBT recipients who received  2 vaccines in the primary series by age. Three
children received either Pediarix or Infanrix, whereas all other patients
received Boostrix.
Table 1
Patient and Graft Demographics of 63 Vaccinated Double-Unit CBT
Recipients
Characteristic Value
Median age, yr (range) 34 (.9-64)
Diagnosis
AML (CR1-3) 31 (49%)
ALL (CR1-4) 11 (17%)
MDS/CML 3 (5%)
Lymphoma 18 (29%)
Conditioning
High dose
Cy/Flu/TBI 1320-1375 26
Thio/Flu/TBI 1320 1
Clo/Mel/Thio 5
Intermediate
Cy/Flu/Thio/TBI 400 17
Reduced intensity
Mel/Flu 3
Nonmyeloablative
Cy/Flu/TBI 200 11
Median engrafting units (range)
8 HLA-allele match* 5/8 (2-7)
Infused TNC  107/kg 2.1 (1.2-11.3)
Infused CD34þ  105/kg .8 (.1-4.1)
Prevaccination rituximab 13 (21%)
GVHD
Grades II-IV acute (grade) 38 (60%)y
Chronic 10 (16%)z
Vaccinated on immunosuppression
No 45 (71%)
Yes 18 (29%)
Median prevaccine immune recovery (range)
CD4þ 577/mL (190-2296)
CD4þCD45RAþ 127/mL (14-1856)
CD19þ 793/mL (0-5533)
IgG 786 mg/dL (502-2965)
AML indicates acute myeloid leukemia; CR, complete response; ALL, acute
lymphoblastic leukemia; MDS, myelodysplastic syndrome; CML, chronic
myelogenous leukemia; Cy, cyclophosphamide; Flu, ﬂudarabine; TBI, total
body irradiation; Thio, thiotepa; Clo, clofarabine; Mel, melphalan; TNC, total
nucleated cell count.
* Donorerecipient HLA match.
y Twenty-seven grade II, 10 grade III, 1 grade IV.
z Nine mild, 1 severe (prior acute: 6 yes, 4 no).
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not receive antieB cell therapy (15 months; range, 7 to 41;
P ¼ .034). Vaccination was also delayed in 42 patients with
prior grades II to IV acute and/or moderate to severe chronic
GVHD with a median onset of 17 months (range, 9 to 45)
post-CBT as compared with 14 months (range, 7 to 33) in
those without clinically signiﬁcant prior GVHD (P ¼ .029).
The median time from GVHD onset to vaccination was 15.7
months (range, 6 to 44).
Responses to Pneumococcal Vaccines
Response to 3 doses of the pneumococcal vaccine was
assessable in 58 patients. Of the 5 other patients, 3 received
only 2 vaccines, 1 with prior pneumococcal infectionwas not
vaccinated, and 1 did not have postvaccine pneumococcal
titers. The 58 assessable patients received Prevnar 7 (n¼ 24),
Prevnar 13 (n ¼ 33), or both (n ¼ 1). Thirty (53%) responded
to all 3 clinically critical pneumococcal serotypes (14, 19F,
and 23F). Response rates by clinically signiﬁcant serotype
(Figure 1) did not differ between children (9/15, 60%) and
adults (21/43, 49%) (P ¼ .555). Among the 28 nonresponders,
19 patients (33%) responded to 1 to 2 critical serotypes and 9
patients (16%) did not respond to any.
There were no signiﬁcant differences between pneumo-
coccal vaccine responses and exposure to prior rituximab,prior clinically signiﬁcant GVHD, or vaccination while on
low-dose immunosuppression therapy. There was also no
association between vaccine response and basic measures of
immune recovery (CD4þ, CD4þCD45RAþ, CD19þ cell counts,
IgG levels, and phytohemagglutinin responses [14] above
versus below the median or in tertiles; data not shown).
Responses to Tdap, HiB, and Polio Vaccines
Responses to Tdap, HiB, and polio were evaluated in all 63
patients. However, only patients who received 2 primary
series vaccines were included in the response evaluation
(from 53 to 60 patients; Figure 2, Table 2). Overall response
rates ranged from 86% to 100% in children and from 53% to
89% in adults. Children had better responses to tetanus (93%
versus 53%, P ¼ .005) and pertussis (100% versus 54%, P ¼
.002) vaccines. There were no differences in response rates
according to prior rituximab (P ¼ .256 to 1.00) or prior clin-
ically signiﬁcant GVHD (P ¼ .155 to 1.00), and no adverse
effects of low-dose immunosuppression therapy were
identiﬁed.
There was a signiﬁcant association between tetanus and
polio responses and measurements of immune recovery.
Patients with CDþ4CD45RAþ counts above the median had
better response rates to tetanus vaccine (79% versus 50%, P ¼
.032), and patients with CD19þ cells above the median had
higher responses to tetanus (86% versus 44%, P ¼ .001) and
polio (92% versus 62%, P ¼ .023) vaccines. Other parameters
Table 2
Response Rates for Primary Series Protein Conjugated Vaccines Including Tdap, HiB, and Polio
Variable Tetanus P Diphtheria P Pertussis P Polio P HiB P
Age < 16 yr (years) 14/15 (93%) .005 12/14 (86%) .310 13/13 (100%) .002 9/10 (90%) .419 14/16 (88%) .99
Age  16 yr (years) 24/45 (53%) 30/45 (68%) 22/41 (54%) 31/43 (72%) 39/44 (89%)
No prior GVHD 14/18 (78%) .155 14/17 (82%) .344 9/15 (60%) .753 12/15 (80%) .736 17/19 (90%) .99
Prior GVHD 24/42 (57%) 28/42 (68%) 26/39 (68%) 28/38 (74%) 36/41 (88%)
No prior rituximab 31/48 (65%) .744 33/47 (70%) .99 29/44 (66%) .728 32/40 (80%) .265 42/47 (89%) .639
Prior rituximab 7/12 (58%) 9/12 (75%) 6/10 (60%) 8/13 (62%) 11/13 (85%)
IST: No 24/42 (57%) .155 26/42 (62%) .013 22/38 (58%) .128 29/38 (76%) .99 37/42 (88%) .99
IST: Yes 14/18 (78%) 16/17 (94%) 13/16 (81%) 11/15 (73%) 16/18 (89%)
Total 60 59 54 53 60
IST indicates immunosuppression therapy.
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phytohemagglutinin responses [14], and IgG levels, were not
signiﬁcantly associated with response.
Hepatitis B Vaccine Responses
Forty-two patients were assessable for hepatitis B
response (2 to 3 vaccines administered). However,10 of these
patients had positive prevaccine titers, so their responses
were considered indeterminate. Of 32 remaining patients
with negative pretransplant titers, 1 of 4 (25%) responded to
2 vaccines and 12 of 28 (43%) to 3 vaccines. Two non-
responders received a second series and responded.
Response to Pneumococcal Boosters
Of 9 patients who did not respond to 1 or more of the
pneumococcal serotypes 14, 19F, and 23F after 3 vaccines in
the primary series, 6 were revaccinated with 1 to 2 Prevnar
boosters. Of these patients, 1 was not evaluated because of
disease relapse and 5 patients all responded (3 patients to 1
booster and 2 patients to 2 boosters).
MMR Vaccine Responses
To date, 59 patients have hadmeasles titers. Nineteen had
positive titers. Twenty-three seronegative patients have
been vaccinated with measles vaccine to date with post-
vaccine titers and 15 (65%) responded (median age, 16 years;
range, 1 to 51). Similarly, of 57 patients with prevaccine
mumps titers, 30%were positive; 10 of 20 patients (50%) with
negative titers responded to mumps vaccine (median age, 23
years; range, 1 to 51). Finally, of 59 patients, 23 (39%) had
positive rubella titers; all 21 patients (100%) with negative
titers vaccinated to date have responded to rubella vaccine.
Vaccine Safety and Survival in Vaccine Recipients
There were no severe adverse side effects reported or
identiﬁed after vaccination. With a median follow-up of 57
months (range, 24 to 100), all vaccinated patients survived.
DISCUSSION
Similar to the young and the elderly, hematopoietic stem
cell transplant recipients rely on herd immunity until they
have sufﬁcient immune reconstitution to facilitate successful
vaccination [26]. In the community such protection is
accomplished through mandatory vaccination in school-
aged children [27], but this has been compromised by an
increase in nonmedical vaccination exemptions [28,29]. Such
exemptions have been linked to outbreaks of vaccine-
preventable illnesses [30,31]. Speciﬁcally, outbreaks of
pneumococcus [32,33], pertussis [34-37], meningococcus
[38-40], polio [41-43], measles [44,45], and mumps [46-48]
have been documented as detailed by the lay press [49-52]and reviewed by Omer et al. [31] and Orenstein et al. [53].
Moreover, Brazilian allograft recipients succumbed to mea-
sles during a national epidemic [54], and a recent measles
outbreak in New York involved exposure in medical facilities
[50]. Also of concern is the recent measles outbreak at Dis-
neyland [55] because patients often choose such destinations
once they can travel post-transplant, and increasingly pa-
tients are also traveling internationally. Decreased vaccina-
tion rates in underdeveloped countries combined with
increased cross-continental travel could further enhance
disease transmission such as polio [53,56], and a risk asso-
ciated with biological warfare has been proposed [57]. These
factors make vaccination of both community and allograft
recipients of paramount importance.
We investigated vaccine responses in adult and pediatric
CBT survivors. Our results have practical clinical importance
and are an important addition to the literature concerning
immune reconstitution. The quality of immune recovery af-
ter CBT is controversial, with some series suggesting delayed
immune reconstitution [58] and others showing better re-
covery especially in those transplanted without antithymo-
cyte globulin [11,12,14-16,59]. We demonstrate that CBT
recipients can respond to protein conjugated vaccines similar
to adult donor allograft recipients. GVHD and rituximab
delayed vaccination but did not preclude responses to pri-
mary series vaccines post-CBT in many patients, and re-
sponses to live vaccines were also observed. Vaccination of
CBT recipients was safe, and vaccinated patients had excel-
lent survival. This is the ﬁrst major analysis of vaccine re-
sponses in CBT especially in a cohort of predominantly (80%)
adult patients. It must be acknowledged that only 63% of
potentially eligible CBT recipients were vaccinated at the
time of analysis, and GVHD was the major contributor to the
delay or inability to vaccinate some patients to date. Mea-
sures to abrogate GVHD [60-63] could improve GVHD control
and thereby potentially enhance the ability to proceed with
vaccination provided these interventions did not unduly
delay immune reconstitution.
Invasive disease caused by pneumococcus occurs with
increased frequency and higher morbidity and mortality in
allograft recipients than in healthy individuals. Imple-
mentation of routine childhood pneumococcal vaccination
has been associated with a reduction in invasive disease. We
focused on the 3 most clinically signiﬁcant serotypes
responsible for pneumococcal infections [64] and showed no
differences in response rates between pediatric and adult
CBT recipients. Although there was no association between
basic measures of immune recovery and vaccine response,
this is likely because most patients have achieved at least
minimal immune recovery before vaccination. In a small
number of nonresponders, pneumococcal boosters were
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response if one is not initially obtained. The recent Centers
for Disease Control and Prevention recommendations for
older adults include the addition of a 23-valent pneumo-
coccal polysaccharide vaccine (PPV23) after PCV13 [65,66],
and this was recently shown to be safe and able to illicit
responses in the transplant recipients upon completion of
the Prevnar series [67].
Response rates of 86% to 100% in children and 53% to 89%
in adults were also achieved with other protein conjugated
vaccines. The responses differed by vaccine type, likely
because of their varying immunogenicity, and tetanus and
pertussis responses were better in children than adults. An
inferior result was demonstrated in patients with low
CD4þCD45RAþ cell counts for tetanus and with a low CD19þ
cell count for polio. In a small cohort responses to hepatitis B
were observed, although overall this vaccine appeared less
effective. From the standpoint of live vaccines, our pre-
liminary data suggest that in patients off immunosuppres-
sion therapy in whom responses to protein conjugated
vaccines were documented, live vaccines are safe and can be
effective. Administration was delayed in adults as compared
with children, likely because of differences in clinical prac-
tice, especially given the need for revaccination before
returning to school. No CBT recipients have been evaluated
for varicella-zoster vaccine responses, and further investi-
gation into MMR and varicella vaccine responses in a larger
cohort is required [18,68].
Our study has several limitations. The sample size was
relatively small, although it did have a signiﬁcant number of
adult patients. Also, although we focused on the pneumo-
coccal serotypes known to be clinically relevant, we
acknowledge that the response to other subtypes could be
valuable. Finally, adverse events were based on chart review
and not recorded prospectively, which may have minimized
the identiﬁcation of minor side effects. Nonetheless, despite
these limitations, the vaccine responses after CBT demon-
strated in this report are similar to other allogeneic trans-
plant groups for protein conjugated vaccines [69]. For
example, the adult CBT response rate to pneumococcal vac-
cine of 53% is similar to the 44% rate in adult donor allograft
recipients reported by Pao et al. [64]. Less information is
available for other vaccines, especially in adults, but re-
sponses for protein conjugated vaccines have been reported
as 36% to 58% for Tdap using 8 mg pertussis toxoid [70,71],
47% to 92% for HiB [72,73], 48% to 95% for polio [73,74], 40% to
64% for hepatitis B [75,76], and 64% to 77% for MMR [77-79].
These rates are similar to those in our series. Only a pro-
spective study with an intention to treat design with con-
current measurements of immune recovery could accurately
compare response rates in deﬁned patient populations
stratiﬁed by hematopoietic stem cell source.
In summary, similar to individuals in the community, CBT
recipients can beneﬁt from immunization against vaccine-
preventable diseases, and although GVHD is the major
cause of vaccination delay, prior GVHD or rituximab and
administration of low-dose immunosuppression therapy are
not prohibitive in many patients. Our strategy to vaccinate
according to immune milestones and document response by
pre- and postvaccination titers is in contrast to the Infectious
Diseases Society of America and the American Society for
Blood and Marrow Transplantation guidelines [17,18,80,81],
which recommend vaccination at 6 months to 1 year without
testing immune function or titers. The optimal immunization
schedule in CBT recipients, however, has not beendetermined. In this study themedian time to vaccinationwas
17 months. It is possible that patients may beneﬁt from
earlier administration of some vaccines. The most appro-
priate timing may also vary by vaccine. Multicenter studies
evaluating pre- and postvaccination titers to determine
optimal vaccination schedule and vaccine efﬁcacy are
needed. Moreover, although our ﬁndings strongly support
vaccination in CBT recipients, multiple unanswered ques-
tions remain that require future prospective evaluation,
including the immunological determinants of response (eg,
the presence of CD19þCD27þIgDþ memory B cells); the role
of boosters to obtain, augment, and maintain responses; the
role of vaccination in patients with positive post-transplant
serologies; and the responses to live vaccines in a larger
patient cohort.
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